SCHEMBL8937310

SCHEMBL8937310

COc1ccccc1/C(=C/C(=O)O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
GRM5 P41594 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
NPC1 O15118 5/20 0.44
RAB9A P51151 3/20 0.44
RORC P51449 1/20 0.44
RORB Q92753 1/20 0.44
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CNR2 P34972 1/20 0.43
KDM4E B2RXH2 1/20 0.43
KCNMA1 Q12791 1/20 0.43
HIF1A Q16665 1/20 0.43
TSHR P16473 1/20 0.42
KCNK3 O14649 1/20 0.42
KCNK9 Q9NPC2 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937318 1.00 LMNA (0.47) LMNAGRM5CA12CA1CA2
SCHEMBL23393319 0.85 RAB9A (0.55) LMNACA12CA1CA2CA9
SCHEMBL21486409 0.85 RAB9A (0.55) LMNACA12CA1CA2CA9
SCHEMBL8999190 0.79 GRM5 (0.48) LMNAGRM5NPC1RAB9ASMN1; SMN2
SCHEMBL8937376 0.76 LMNA (0.48) LMNANPC1RAB9AMAPTSMN1; SMN2
SCHEMBL8937382 0.76 LMNA (0.48) LMNANPC1RAB9AMAPTSMN1; SMN2
SCHEMBL8937521 0.76 LMNA (0.48) LMNANPC1RAB9AMAPTSMN1; SMN2
SCHEMBL7823036 0.76 CA12 (0.54) LMNACA12CA1CA2CA9
SCHEMBL8937361 0.75 HPGD (0.50) CA1CA2RAB9AMAPTKDM4E
SCHEMBL8937315 0.75 HPGD (0.50) CA1CA2RAB9AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed